Table 3.

Clinical outcomes and hip function from baseline to 52 weeks between the TNF-α inhibitor group and control group.

	Groups	Baseline	Treatment 52 weeks	p-Value
ESR (mm)	TNF-α group	26.91 ± 14.90	11.01 ± 12.58	0.000
	Control group	25.04 ± 14.34	17.07 ± 12.23	0.000
	p-Value	0.367	0.002
CRP (mg/L)	TNF-α group	1.42 ± 1.28	0.73 ± 1.17	0.000
	Control group	1.27 ± 1.23	0.88 ± 0.91	0.047
	p-Value	0.364	0.371
Harris	TNF-α group	67.65 ± 9.26	92.26 ± 7.06	0.000
	Control group	66.27 ± 10.85	82.95 ± 7.93	0.000
	p-Value	0.313	0.000
BASDAI	TNF-α group	5.76 ± 1.20	2.16 ± 1.90	0.000
	Control group	5.53 ± 1.29	2.81 ± 1.42	0.000
	p-Value	0.199	0.000
ASDAS-CRP	TNF-α group	2.78 ± 0.62	1.06 ± 0.46	0.000
	Control group	2.53 ± 0.57	1.40 ± 0.63	0.000
	p-Value	0.004	0.000
ASDAS-ESR	TNF-α group	2.76 ± 0.60	1.42 ± 0.60	0.000
	Control group	2.90 ± 0.67	1.88 ± 0.62	0.000
	p-Value	0.124	0.000

ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Ankylosing Spondylitis Disease Activity Score.